Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Carbocisteine→

Carbocisteine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
638-23-3
Molecular formula
C5H9NO4S
Molecular weight
179.2 g/mol
Drug class
Mucolytic and mucoregulator (S-carboxymethyl-L-cysteine)
Mechanism of action
Modifies the composition and amount of respiratory mucus glycoproteins, including the acid-to-neutral glycoprotein ratio, and reduces goblet-cell hyperplasia; this helps restore more normal mucus characteristics in hypersecretory respiratory disorders.
Indications / reported uses
  • Management of respiratory disorders characterised by abnormal or excessive mucus, such as chronic bronchitis and other product-specified respiratory conditions

Sources: UK SmPC — Carbocisteine 375 mg capsules · UK SmPC — Carbocisteine 750 mg/5 ml syrup · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Carbocisteine Environmental Risk Assessment (ERA) (the Carbocisteine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.